KLOW
Also called GHK-Cu + BPC-157 + TB-500 + KPV
No single human route established in this referenceEvidence gap
Research reference
Evidence gap
KLOW blend evidence gap
No source-backed schedule
No established human course
When results may show
KLOW
Evidence gap- When change was measured
- No measured human outcome window identified for this exact material.
- When to assess
- No established human course
- Conditions and limitations
- No exact-product primary protocol located in this review. Ingredient papers do not establish this four-compound blend's ratio, safety, amount or course. No exact-blend study was located.
- When to stop
- The measured study window is not a validated personal quit rule. Do not increase or prolong exposure because an expected result is absent; severe or persistent reactions need prompt clinical review.
No direct outcome source identified. See the compound page for evidence grading.
Research timing is descriptive, not a promise or personal instruction. A severe or persistent reaction needs prompt clinical review. This is not medical advice.
Combination evidence and cautions
What is known and unknown about KLOW alongside other compounds or medicines.
What is in a 80 mg KLOW vial
| Component | Share | Per vial |
|---|---|---|
| GHK-Cu | 63% | 50 mg |
| BPC-157 | 13% | 10 mg |
| TB-500 | 13% | 10 mg |
| KPV | 13% | 10 mg |
Every draw has these same proportions.
Modelled level — every day
One curve per component: the components clear at very different rates.
GHK-Cu (in KLOW)BPC-157 (in KLOW)TB-500 (in KLOW)KPV (in KLOW)